122 related articles for article (PubMed ID: 38176009)
21. Detection of prostate cancer biomarkers via a SERS-based aptasensor.
Zhao J; Wang J; Liu Y; Han XX; Xu B; Ozaki Y; Zhao B
Biosens Bioelectron; 2022 Nov; 216():114660. PubMed ID: 36099835
[TBL] [Abstract][Full Text] [Related]
22. Dual-color quantum dots nanobeads based suspension microarray for simultaneous detection of dual prostate specific antigens.
Min X; Huang S; Yuan C
Anal Chim Acta; 2022 Apr; 1204():339704. PubMed ID: 35397909
[TBL] [Abstract][Full Text] [Related]
23. [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
Ohuchi H; Mikata K; Miyoshi Y; Ohta J; Osada Y; Uemura H; Yao M; Takeda M; Noguchi S; Kubota Y; Hosaka M; Jinza S; Asakura T; Ebato T
Nihon Hinyokika Gakkai Zasshi; 2000 Dec; 91(12):695-9. PubMed ID: 11201129
[TBL] [Abstract][Full Text] [Related]
24. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
[TBL] [Abstract][Full Text] [Related]
25. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
[TBL] [Abstract][Full Text] [Related]
27. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
[TBL] [Abstract][Full Text] [Related]
28. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
29. Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone.
Liu B; Pan TJ
Urologia; 2014; 81(3):173-6. PubMed ID: 24557815
[TBL] [Abstract][Full Text] [Related]
30. Dual-labeled chemiluminescence enzyme immunoassay for simultaneous measurement of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA).
Zhao L; Wang D; Shi G; Lin L
Luminescence; 2017 Dec; 32(8):1547-1553. PubMed ID: 28636187
[TBL] [Abstract][Full Text] [Related]
31. Plasmonic Cu
Yang L; Gao MX; Zou HY; Li YF; Huang CZ
Anal Chem; 2018 Oct; 90(19):11728-11733. PubMed ID: 30141616
[TBL] [Abstract][Full Text] [Related]
32. Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer.
Stefancu A; Moisoiu V; Couti R; Andras I; Rahota R; Crisan D; Pavel IE; Socaciu C; Leopold N; Crisan N
Nanomedicine (Lond); 2018 Oct; 13(19):2455-2467. PubMed ID: 30284481
[TBL] [Abstract][Full Text] [Related]
33. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Thakur V; Singh PP; Talwar M; Mukherjee U
Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
[TBL] [Abstract][Full Text] [Related]
34. The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml.
Wu CT; Chuang CK; Chou CC; Chu SH; Chen HW; Chen CS; Chiang YJ; Liao SK
Chang Gung Med J; 2000 Mar; 23(3):142-8. PubMed ID: 15641217
[TBL] [Abstract][Full Text] [Related]
35. Colorimetric and Fluorescent Dual-Mode Immunoassay Based on Plasmon-Enhanced Fluorescence of Polymer Dots for Detection of PSA in Whole Blood.
You PY; Li FC; Liu MH; Chan YH
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9841-9849. PubMed ID: 30784256
[TBL] [Abstract][Full Text] [Related]
36. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
37. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis.
Huang Y; Li ZZ; Huang YL; Song HJ; Wang YJ
Medicine (Baltimore); 2018 Mar; 97(13):e0249. PubMed ID: 29595681
[TBL] [Abstract][Full Text] [Related]
38. A portable chemiluminescence imaging immunoassay for simultaneous detection of different isoforms of prostate specific antigen in serum.
Liu A; Zhao F; Zhao Y; Shangguan L; Liu S
Biosens Bioelectron; 2016 Jul; 81():97-102. PubMed ID: 26922048
[TBL] [Abstract][Full Text] [Related]
39. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
40. Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml
Gao XD; Miao Q; Zhang JL; Zhai JZ; Gui XM; Cai YH; Niu Q; Cai B
Asian J Androl; 2022; 24(2):195-200. PubMed ID: 34916475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
